STAAR Surgical Reports Second Quarter 2026 Results
Business Wire•12/08/2026•16:01 ET
0
Whiz Insights
Adjusted EBITDA(1) of $20.0 million, or $0.39 per diluted share
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the second quarter ended July 3, 2026.
Get started
Create a free account to read the full story.